Miscarriage · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin showed no clear difference in miscarriage rate per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Live birth rate per woman · subfertile women with polycystic ovary syndrome
Metformin may leads to higher live birth rate (per woman) compared with placebo co‐treatment (low certainty).
1 finding from 1 review
Multiple pregnancy rate · subfertile women with polycystic ovary syndrome
Metformin showed no clear difference in multiple pregnancy rate (per woman) compared with placebo co‐treatment (low certainty).
1 finding from 1 review
Ongoing pregnancy · subfertile women with polycystic ovary syndrome
Metformin may leads to higher ongoing pregnancy rate (per woman) compared with placebo co‐treatment (low certainty).
1 finding from 1 review
Clinical pregnancy rate · subfertile women with polycystic ovary syndrome
Metformin may leads to higher clinical pregnancy rate (per woman) compared with placebo co‐treatment (low certainty).
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight Average endpoint/change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
It is very uncertain whether metformin changes leaving the study early: for any reason compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
Metformin showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).
1 finding from 1 review
Diabetes · Adults with mental disorders in low‐ and middle‐income countries
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Drop‐out Objective · Adults with mental disorders in low‐ and middle‐income countries
Metformin showed no clear difference in drop‐outs (12 to 14 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Fasting blood glucose (mg/dL) · Adults with mental disorders in low‐ and middle‐income countries
2 findings from 1 review
Body‐mass index (BMI) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Hypertensive disorders of pregnancy · women with gestational diabetes mellitus
Metformin showed no clear difference in hypertensive disorders of pregnancy compared with glibenclamide ‐ maternal outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women with gestational diabetes mellitus
Metformin showed no clear difference in caesarean section compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Development of type 2 diabetes ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Perineal trauma · women with gestational diabetes mellitus
Metformin showed no clear difference in perineal trauma compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review